London, UK – 10 January 2022. Actimed Therapeutics Ltd, the clinical stage company focused on bringing innovation to the treatment of muscle wasting disorders today announced that its Chief Executive Officer, Robin Bhattacherjee will be presenting at the Biotech Showcase 2022 conference with an online presentation.

The conference takes place virtually on January 10-13th 2022 and registered attendees can access the Company’s recorded company presentation with on-demand access at their convenience.

Mr Bhattacherjee will present an update on progress by Actimed including the recent initiation of its first clinical study of the pharmacokinetics and pharmacodynamics (PK/PD) for a new salt of S-pindolol (ACM-001.01) to treat cancer cachexia announced in December 2021 - Actimed Therapeutics Achieves Major Corporate Milestone

Dr Frank Misselwitz, the Chief Medical Officer of Actimed will also be attending the conference as an Actimed delegate alongside Mr Bhattacherjee.

Robin Bhattacherjee commented, “We have made tremendous progress over the last year culminating in the recent initiation of the first clinical study for our lead asset which we hope will become the first globally approved product to treat cancer cachexia. I am delighted to be able to share these developments with the audience at Biotech Showcase and look forward to fruitful discussions with investors and other participants.”